63 related articles for article (PubMed ID: 21266106)
1. Depletion of Neuroguidin/CANu1 sensitizes human osteosarcoma U2OS cells to doxorubicin.
Park JH; Sihn CR; Lee YS; Lee SJ; Kim SH
BMB Rep; 2011 Jan; 44(1):46-51. PubMed ID: 21266106
[TBL] [Abstract][Full Text] [Related]
2. Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway.
Spina A; Sorvillo L; Di Maiolo F; Esposito A; D'Auria R; Di Gesto D; Chiosi E; Naviglio S
J Cell Physiol; 2013 Jan; 228(1):198-206. PubMed ID: 22674530
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis.
Yuan XW; Zhu XF; Huang XF; Sheng PY; He AS; Yang ZB; Deng R; Feng GK; Liao WM
Acta Pharmacol Sin; 2007 Nov; 28(11):1835-41. PubMed ID: 17959036
[TBL] [Abstract][Full Text] [Related]
4. Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing.
Zhao Y; Zhang CL; Zeng BF; Wu XS; Gao TT; Oda Y
Biochem Biophys Res Commun; 2009 Dec; 390(3):642-7. PubMed ID: 19818735
[TBL] [Abstract][Full Text] [Related]
5. Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma.
Orosco A; Fromigué O; Bazille C; Entz-Werle N; Levillain P; Marie PJ; Modrowski D
Cancer Res; 2007 Apr; 67(8):3708-15. PubMed ID: 17440083
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-induced cell death requires cathepsin B in HeLa cells.
Bien S; Rimmbach C; Neumann H; Niessen J; Reimer E; Ritter CA; Rosskopf D; Cinatl J; Michaelis M; Schroeder HW; Kroemer HK
Biochem Pharmacol; 2010 Nov; 80(10):1466-77. PubMed ID: 20709028
[TBL] [Abstract][Full Text] [Related]
7. CANu1, a novel nucleolar protein, accumulated on centromere in response to DNA damage.
Sihn CR; Lee YS; Jeong JS; Park K; Kim SH
Genes Cells; 2008 Aug; 13(8):787-96. PubMed ID: 18547334
[TBL] [Abstract][Full Text] [Related]
8. IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines.
Luk F; Yu Y; Walsh WR; Yang JL
Cancer Invest; 2011 Oct; 29(8):521-32. PubMed ID: 21843050
[TBL] [Abstract][Full Text] [Related]
9. Intact cell evidence for the early synthesis, and subsequent late apopain-mediated suppression, of poly(ADP-ribose) during apoptosis.
Rosenthal DS; Ding R; Simbulan-Rosenthal CM; Vaillancourt JP; Nicholson DW; Smulson M
Exp Cell Res; 1997 May; 232(2):313-21. PubMed ID: 9168807
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative and antimigratory effects of doxorubicin in human osteosarcoma cells exposed to extracellular matrix.
Harisi R; Dudás J; Tímár F; Pogány G; Paku S; Tímár J; Kovalszky I; Szendroi M; Jeney A
Anticancer Res; 2005; 25(2A):805-13. PubMed ID: 15868912
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition of tissue factor by siRNA enhances doxorubicin-induced apoptosis in human neuroblastoma].
Fang J; Tang H; Xia LH; Zhou MX; Chen Y; Wei WN; Hu Y; Song SJ
Zhonghua Xue Ye Xue Za Zhi; 2007 Sep; 28(9):594-7. PubMed ID: 18246814
[TBL] [Abstract][Full Text] [Related]
12. The effect of 3-aminobenzamide, inhibitor of poly(ADP-ribose) polymerase, on human osteosarcoma cells.
De Blasio A; Musmeci MT; Giuliano M; Lauricella M; Emanuele S; D'Anneo A; Vassallo B; Tesoriere G; Vento R
Int J Oncol; 2003 Dec; 23(6):1521-8. PubMed ID: 14612922
[TBL] [Abstract][Full Text] [Related]
13. Curcumin induces cell cycle arrest and apoptosis in human osteosarcoma (HOS) cells.
Lee DS; Lee MK; Kim JH
Anticancer Res; 2009 Dec; 29(12):5039-44. PubMed ID: 20044614
[TBL] [Abstract][Full Text] [Related]
14. SM‑164 enhances the antitumor activity of adriamycin in human U2‑OS cells via downregulation of X‑linked inhibitor of apoptosis protein.
Chen J; Chen X; Chen X; Sun H; Yang D
Mol Med Rep; 2019 Jun; 19(6):5079-5086. PubMed ID: 31059038
[TBL] [Abstract][Full Text] [Related]
15. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
Yang C; Hornicek FJ; Wood KB; Schwab JH; Mankin H; Duan Z
Cancer Chemother Pharmacol; 2009 Aug; 64(3):607-14. PubMed ID: 19125251
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
[TBL] [Abstract][Full Text] [Related]
17. Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins.
Mirandola P; Sponzilli I; Gobbi G; Marmiroli S; Rinaldi L; Binazzi R; Piccari GG; Ramazzotti G; Gaboardi GC; Cocco L; Vitale M
Int J Oncol; 2006 Jan; 28(1):127-33. PubMed ID: 16327988
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy by downregulating survivin.
Zou J; Gan M; Mao N; Zhu X; Shi Q; Yang H
Arch Med Res; 2010 Apr; 41(3):162-9. PubMed ID: 20682173
[TBL] [Abstract][Full Text] [Related]
19. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients.
Pasello M; Hattinger CM; Stoico G; Manara MC; Benini S; Geroni C; Mercuri M; Scotlandi K; Picci P; Serra M
Eur J Cancer; 2005 Sep; 41(14):2184-95. PubMed ID: 16140527
[TBL] [Abstract][Full Text] [Related]
20. E2F activity is essential for survival of Myc-overexpressing human cancer cells.
Santoni-Rugiu E; Duro D; Farkas T; Mathiasen IS; Jäättelä M; Bartek J; Lukas J
Oncogene; 2002 Sep; 21(42):6498-509. PubMed ID: 12226753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
